NP / PA
Nea Reliant Health Care Professionals INC
Nea Reliant Health Care Professionals INC was paid $1.86M by Medicaid between Jan 2018 and Nov 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoNEA RELIANT HEALTH CARE PROFESSIONALS INC
BONO, AR 72416
BONO, AR 72416
33aNPI1467829804assigned 09/01/2015
33bProvider typeFamily Nurse Practitioner
28Total paid$1.86M
24GClaims79,769
24DCodes billed82
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Family Nurse Practitioner providers in Arkansas
Rank by total paid#1 of 89
Median peer was paid$7K
This provider vs. median249×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,581 | $186K | |
| 2019 | 10,445 | $146K | |
| 2020 | 11,623 | $370K | |
| 2021 | 17,674 | $592K | |
| 2022 | 10,096 | $332K | |
| 2023 | 8,831 | $129K | |
| 2024incomplete | 5,519 | $103K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 15,958 | 12,599 | $516K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 25% | 9,982 | 9,139 | $463K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 20% | 9,116 | 8,104 | $380K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 10,672 | 9,151 | $252K |
| 80305 | 1.1% | 7,347 | 5,681 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 160 | 133 | $14K |
| 80348 | <1% | 585 | 554 | $12K | |
| 80346 | <1% | 585 | 554 | $12K | |
| 80354 | <1% | 583 | 553 | $12K | |
| 80373 | <1% | 584 | 554 | $11K | |
| 80370 | <1% | 584 | 554 | $10K | |
| 80364 | <1% | 480 | 449 | $9K |
70 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 572 | $9K |
| 80325 | <1% | 585 | $9K | |
| 80355 | <1% | 588 | $8K | |
| 80368 | <1% | 585 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 353 | $8K |
| 80349 | <1% | 584 | $7K | |
| 80366 | <1% | 548 | $7K | |
| 80323 | <1% | 237 | $7K | |
| 80358 | <1% | 349 | $7K | |
| 80365 | <1% | 363 | $6K | |
| 80353 | <1% | 345 | $5K | |
| 80360 | <1% | 335 | $5K | |
| 80338 | <1% | 222 | $4K | |
| 81003 | <1% | 5,508 | $4K | |
| 99406 | <1% | 481 | $4K | |
| 93880 | <1% | 28 | $4K | |
| 80357 | <1% | 222 | $3K | |
| 80359 | <1% | 222 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 211 | $3K |
| 80356 | <1% | 109 | $2K | |
| 80061 | Lipid panel | <1% | 403 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 616 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 862 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 300 | $2K |
| 99454 | <1% | 126 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,707 | $2K |
| 80362 | <1% | 363 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 129 | $2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 19 | $2K |
| 80050 | General health panel | <1% | 53 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 319 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 296 | $1K |
| 84439 | <1% | 213 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 78 | $1K |
| 82607 | <1% | 137 | $976.41 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 17 | $715.51 |
| 84480 | <1% | 48 | $445.50 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 17 | $326.92 |
| 99491 | Ccm add 20min | <1% | 36 | $312.66 |
| 94010 | <1% | 19 | $280.11 | |
| 99407 | <1% | 24 | $275.00 | |
| 72100 | <1% | 25 | $250.52 | |
| 83735 | <1% | 69 | $241.62 | |
| 84436 | <1% | 49 | $195.80 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 366 | $184.77 |
| 99490 | Ccm add 20min | <1% | 21 | $139.50 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32 | $132.99 |
| 99457 | <1% | 125 | $103.47 | |
| 86140 | <1% | 47 | $81.66 | |
| 85651 | <1% | 58 | $77.18 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 31 | $58.51 |
| 80076 | <1% | 13 | $58.35 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18 | $31.68 |
| 96127 | <1% | 19 | $29.37 | |
| 3078F | <1% | 34 | $10.00 | |
| 3074F | <1% | 143 | $10.00 | |
| 96160 | <1% | 61 | $0.51 | |
| 1159F | 0% | 953 | $0.00 | |
| 1160F | 0% | 1,015 | $0.00 | |
| 99487 | Ccm add 20min | 0% | 16 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 18 | $0.00 |
| 3008F | 0% | 716 | $0.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 29 | $0.00 |
| 1125F | 0% | 685 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 69 | $0.00 |
| 1126F | 0% | 124 | $0.00 | |
| 1170F | 0% | 85 | $0.00 | |
| 3079F | 0% | 55 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| 94760 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERGMAN, JEREMY (OWNER)